ZFGN


Stock Update (NASDAQ:ZFGN): Zafgen Inc Announces 3Q:16 Financial Results

Zafgen Inc (NASDAQ:ZFGN) announced its third quarter 2016 financial results. “We have leveraged our experience with the MetAP2 pathway to develop ZGN-1061, a …

Stock Update (NASDAQ:ZFGN): Zafgen Inc Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061

Zafgen Inc (NASDAQ:ZFGN) announced that the Company has recently initiated dosing in the multiple ascending dose (MAD) cohorts of its ongoing Phase 1 clinical …

Canaccord Weighs in on Zafgen Inc (ZFGN) in Wake of Suspended Development for Weight Loss Drug Beloranib

Zafgen Inc (NASDAQ:ZFGN) is shooting for a refocus after an FDA meeting has led to suspension of future development for weight loss agent …

Cowen Downgrades Zagfen Inc (ZFGN) Following Shutting Down of a Pipeline Drug

Analyst Phil Nadeau of Cowen downgraded shares of Zafgen Inc (NASDAQ:ZFGN) from Outperform to Market Perform, after the biotech company terminated one of its pipeline drugs, …

Company Update (NASDAQ:ZFGN): Zafgen Inc Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061

Zafgen Inc (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced …

Company Update (NASDAQ:ZFGN): Zafgen Inc Reports First Quarter 2016 Financial Results

Zafgen Inc (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today …

Healthcare Analysts Maintain Positive Outlook On Allergan plc Ordinary Shares (AGN) And Zafgen Inc (ZFGN) Following Recent Announcements

Healthcare analysts explain why they are bullish on Allergan plc Ordinary Shares (NYSE:AGN) and Zafgen Inc (NASDAQ:ZFGN). Although many investors are worried that …

Company Update (NASDAQ:ZFGN): Zafgen Inc Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016

Zafgen Inc (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, …

Monday Morning’s Market Insights: Seadrill Ltd (SDRL), Tesla Motors Inc (TSLA), Virgin America Inc (VA), Zafgen Inc (ZFGN)

Seadrill Ltd (NYSE:SDRL) is down 4% in pre-market trading following news that it is in talks with various firms to restructure loans and …

Company Update (NASDAQ:ZFGN): Zafgen Inc’s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint

Zafgen Inc (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts